Thank you, Manny, and good morning, everyone. The second quarter of 2024 was our 3rd consecutive quarter of strong top- and bottom-line results, coinciding with the formal institution of the various Project Phoenix initiatives as our new standard operating procedure. Given this new focus and enhanced processes, we once again met or exceeded our outlook in the second quarter. And as such, we remain on target to achieve one of our all-time high performance adjusted EBITDA years. This was the ultimate objective of Project Phoenix, leveraging our core competencies to unlock our inherent value. Revenue in the second quarter was up meaningfully for the 3rd consecutive quarter, increasing nearly 8%. Consistent with the first quarter, about one quarter of our overall growth was attributable to price increases, where we have taken pricing actions starting primarily with smaller- or mid-sized customers. In addition, growth was net of certain work that we vacated, because it did not meet the new profitability benchmarks established by our commercial function. Aerospace and Defense continued its strong growth trajectory, with revenue being up 17.5% in the second quarter, on the heels of having been up 18.9% in the first quarter, making this its third consecutive quarter of favorable results. Commercial aerospace continues to be extremely strong and we are also generating significant growth in the private space industry as well as a result of the increase in number of launches. We are channeling incremental capital into our Aerospace and Defense business in order to capitalize on what we see as a unique window in the market to accelerate growth. Capital funds are going primarily to our Shop Laboratories, where we are expanding the services that we offer to help debottleneck our customer supply chain constraints. As Manny indicated, we expect strong performance from the higher margin Aerospace and Defense industry throughout the year. Our Oil& Gas industry revenue has also continued to be very resilient in the second quarter of 2024, up 3% over the prior year quarter after having been up 14.7% in the first quarter on the strength of a robust spring turnaround season. Actually, all of our end markets were up in the second quarter compared to the prior year quarter, demonstrating the diversity of the industries that we serve. Both growth profit and margin expanded again in the second quarter, primarily attributable to a favorable sales mix change and lower healthcare claims expense, as well as due to the favorable impact of Project Phoenix actions realized in 2024, including pricing increases achieved. Selling, general and administrative expenses were down both sequentially and year-over-year, although admittedly somewhat modestly and less than expected in light of our cost reduction plan. For the quarter, our SG&A was 21.6% of revenue and was 22% of revenue for the 6 months ended June 30. As Manny mentioned earlier, we remain committed to achieving our goal of reducing SG&A to approximately 21% of full year 2024 revenue. Note that our original EBITDA outlook for 2024 anticipated in incremental year-over-year gross profit benefit of $3 million and SG&A benefit of $12 million due to Project Phoenix initiatives. Based upon our implementation of Project Phoenix, we have validated this cost savings of $15 million in aggregate. However, this benefit is now revised to be $7 million of cost of revenue reduction and $8 million of SG&A reduction savings in fiscal 2024. Therefore, although we will still realize a $15 million aggregate improvement to adjusted EBITDA in 2024 attributable to these items, there will be a change in the distribution of savings between the cost of revenue and SG&A line respectively. However, this change has no net impact on our outlook for adjusted EBITDA for fiscal 24. Nevertheless, the company’s primary objective is to create shareholder value by improving our bottom-line profitability. And in the second quarter, we made significant progress on this front, with GAAP net income of $6.4 million or $0.20 per diluted share, up from $0.3 million or $0.01 per share a year ago. And after rising 55% in the first quarter, adjusted EBITDA was up 44% to $22 million in the second quarter and stands at $38.3 million for the first half of 2024. With regard to cash flows, net cash provided by operating activities was $5.2 million and free cash flow was negative $6.9 million for the first half of 2024. Each of these metrics were well below the prior year comparable metric. And both were adversely impacted by an increase in receivables and unbilled receivables in progress. This was primarily due to a lack of prioritization and focus by management along with the timing of invoicing associated with customer projects and the nature of some of the work that was completed in the second quarter. As Manny mentioned earlier, cash from operations and free cash flow performance for the year and year-to-date periods did not meet the company’s expectations. The company is intently focused on improving this performance over the remainder of the year. Specifically, we will work with operations management via additional oversight and attention by senior management to drive down both accounts receivable and unbilled work in process. Our goal is that together with earnings over the second half of the year to generate over $40 million in free cash flow, which will enable us to meet our reaffirmed free cash flow outlook of $34 million to $38 million for the full year. Interest expense was $4.4 million for the quarter, up from a year ago, but essentially unchanged from the first quarter. We expect to reduce interest expense for the remaining quarters of 2024 in two ways: first, by reducing leverage, which will lead to a lower interest rate; and second, by decreasing the amount of outstanding borrowings. This should lead to a gradual decrease in interest expense over the second half of 2024. Our trailing 12-month bank-defined leverage ratio on our credit facility dropped to below 3 times during the second quarter of 2024, and it was 2.78 as of June 30. This is the lowest ratio this is – lowest this ratio has been since the third quarter of 2018. Based on our current projections, we anticipate further reductions to our leverage ratio throughout 2024 due to the anticipated increase in our trailing 12-month EBITDA and debt reductions. Over the past few years, we have primarily used our free cash flow to pay down over $90 million of outstanding borrowings. As we approach our year end 2.5 times leverage ratio goal, we now believe that capital expenditures that support our organic growth and supply superior returns at times may be a superior use of our free cash flow. Again, each of these uses will be considered as we move forward. Our overall effective income tax rate was 15.5% in the second quarter, which benefited from the discrete benefit recognized during the second quarter. We expect our full year effective income tax rate to be in the low-20% range for the full year. There is a true sense required at Mistras like never before, and it has led to the vigor with which teams have attacked the various Project Phoenix initiatives and market opportunities. These efforts are being rewarded with tremendous results. I’m extremely optimistic, not only about this year, but about 2025 and beyond, as we continue to implement initiatives that leverage the unparalleled talent, experience and capabilities and knowledge that has made Mistras a leader in the industry for over 40 years. We sincerely appreciate your continued support and expect to reward your patients with significantly improved results over a remainder of 2024 and for the longer term. At this time, I’d like to turn the call back over to Manny for his closing remarks, before we move on to take your questions.